Journal of Clinical Oncology, Vol 5, 1942-1951, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

PB Chapman, TJ Lester, ES Casper, JL Gabrilove, GY Wong, SJ Kempin, PJ Gold, S Welt, RS Warren and HF Starnes
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Twenty-six patients with advanced cancer refractory to standard therapy were treated with recombinant human tumor necrosis factor (rTNF) in a study aimed at determining the toxicity and tolerance of rTNF and at seeking evidence of antitumor activity. The study design involved two treatments per week for 4 weeks with alternating subcutaneous and intravenous (IV) administration, and weekly dose escalation through four levels in each patient. The dose range was 1 to 200 micrograms/m2 for IV bolus injection, and 5 to 250 micrograms/m2 for subcutaneous injection. Thirteen patients completed the full course. Early discontinuation of treatment was related to rTNF toxicity in seven cases. The major side effects were rigors, fever, headache, fatigue, and hypotension. Acute changes in granulocyte, lymphocyte, and monocyte counts, changes in serum zinc levels and plasma cortisol levels consistent with an acute phase response, and inflammation at the site of subcutaneous injection were also seen. At doses of 125 to 250 micrograms/m2, inflammation at the subcutaneous injection site was unacceptably severe. Minor changes were seen in hemostatic parameters. Hypotension was corrected by fluid administration and did not require treatment with vasopressors. Initial serum concentrations of rTNF were measured at five minutes after IV administration and were found to range from 2.5 ng/mL after a dose of 35 micrograms/m2 to 80 ng/mL after a dose of 200 micrograms/m2. The half-life of rTNF in the blood was 20 minutes. A decrease in lymph node size was observed in a patient with B cell lymphoma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Hohenberger and W. M. Wysocki Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist, February 1, 2008; 13(2): 175 - 186. [Abstract] [Full Text] [PDF]

				K. Ando, T. Ohmori, F. Inoue, T. Kadofuku, T. Hosaka, H. Ishida, T. Shirai, K. Okuda, T. Hirose, N. Horichi, et al. Enhancement of Sensitivity to Tumor Necrosis Factor {alpha} in Non-Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib Clin. Cancer Res., December 15, 2005; 11(24): 8872 - 8879. [Abstract] [Full Text] [PDF]

				A. J. Mundt, S. Vijayakumar, J. Nemunaitis, A. Sandler, H. Schwartz, N. Hanna, T. Peabody, N. Senzer, K. Chu, C. S. Rasmussen, et al. A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities Clin. Cancer Res., September 1, 2004; 10(17): 5747 - 5753. [Abstract] [Full Text] [PDF]

				D. S. Wheeler, J. D. Catravas, K. Odoms, A. Denenberg, V. Malhotra, and H. R. Wong Epigallocatechin-3-gallate, a Green Tea-Derived Polyphenol, Inhibits IL-1{beta}-Dependent Proinflammatory Signal Transduction in Cultured Respiratory Epithelial Cells J. Nutr., May 1, 2004; 134(5): 1039 - 1044. [Abstract] [Full Text] [PDF]

				N. Senzer, S. Mani, A. Rosemurgy, J. Nemunaitis, C. Cunningham, C. Guha, N. Bayol, M. Gillen, K. Chu, C. Rasmussen, et al. TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors J. Clin. Oncol., February 15, 2004; 22(4): 592 - 601. [Abstract] [Full Text] [PDF]

				A. L. Pecora, N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, et al. Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers J. Clin. Oncol., May 1, 2002; 20(9): 2251 - 2266. [Abstract] [Full Text] [PDF]

				H. Meeran and M. Messent The systemic inflammatory response syndrome Trauma, April 1, 2001; 3(2): 89 - 100. [Abstract] [PDF]

				P. M. Wallace, J. F. MacMaster, K. A. Rouleau, T. J. Brown, J. K. Loy, K. L. Donaldson, and A. F. Wahl Regulation of Inflammatory Responses by Oncostatin M J. Immunol., May 1, 1999; 162(9): 5547 - 5555. [Abstract] [Full Text] [PDF]

				E. Abraham, M. P. Glauser, T. Butler, J. Garbino, D. Gelmont, P. F. Laterre, K. Kudsk, H. A. Bruining, C. Otto, E. Tobin, et al. p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial JAMA, May 21, 1997; 277(19): 1531 - 1538. [Abstract] [PDF]

				P. Sorkin, S. Abu-Abid, D. Lev, M. Gutman, D. Aderka, P. Halpern, A. Setton, N. Kudlik, J. Bar-On, V. Rudich, et al. Systemic Leakage and Side Effects of Tumor Necrosis Factor {alpha} Administered Via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment Arch Surg, October 1, 1995; 130(10): 1079 - 1084. [Abstract] [PDF]

				E. Abraham, R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Allred, et al. Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor {alpha} in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial JAMA, March 22, 1995; 273(12): 934 - 941. [Abstract] [PDF]

				R. Porat, H.N. Paddock, F. Cominelli, M.N. Marra, R.W. Scott, S.D. Schwaitzberg, and C.A. Dinarello Effects of bactericidal/permeability-increasing protein on endotoxin-induced fever and Escherichia coli-induced shock in rabbits Innate Immunity, February 1, 1995; 2(1): 9 - 18. [Abstract] [PDF]

				C. A. Dinarello, J. A. Gelfand, and S. M. Wolff Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome JAMA, April 14, 1993; 269(14): 1829 - 1835. [Abstract] [PDF]

				L. Sanchez-Cantu, H. N. Rode, T. J. Yun, and N. V. Christou Tumor Necrosis Factor Alone Does Not Explain the Lethal Effect of Lipopolysaccharide Arch Surg, February 1, 1991; 126(2): 231 - 235. [Abstract] [PDF]